Safety and efficacy of Deucravacitinib for moderate to severe plaque psoriasis: A meta‐analysis
Skin Research and Technology · 2024
DOI: 10.1111/srt.13855 ↗At a glance
Metaanalyse in Skin Research and Technology, 2024. Written by Caixia Hu and 4 co-authors. Institution: Department of Dermatology, the Forth Hospital of Hebei Medical University, Shijiazhuang, China. Major MEDLINE topics: Psoriasis, Randomized Controlled Trials as Topic. Cited 2 times so far (Crossref); 19 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Background
To systematically evaluate the safety and efficacy of Deucravacitinib for moderate to severe plaque psoriasis. Materials and Methods Randomized controlled trials (RCTs) of Deucravacitinib for moderate to severe plaque psoriasis in PubMed, Cochrane Library, Embase, and Web of Science were searched from database establishment to April 2023. Literature quality was independently evaluated by two investigators using the Cochrane risk‐of‐bias assessment tool, and the systematic analysis was made using StateSE15 and RevMan 5.3 software.
Results
Four RCTs were included, including 1751 patients with moderate to severe plaque psoriasis. Meta‐analysis showed that the differences in efficacy and adverse events (AEs) between the Deucravacitinib group and placebo group were significant ( p < 0.05). The patients in the Deucravacitinib group took orally 3–12 mg daily for 12 sequential weeks or 6 mg daily for 52 sequential weeks. Psoriasis Area and Severity Index (PASI) reduced by 75% (PASI 75), (PASI 90), and (PASI 100), static Physician Global Assessment (sPGA) of 0 or 1 (sPGA 0/1), Dermatology Life Quality Index of 0 or 1 (DLQI 0/1), and Psoriasis Symptoms and Signs Diary (PSSD) were significantly higher in the Deucravacitinib group compared to the placebo group, with significant differences ( p < 0.05). The most frequently encountered AEs after treatment in the Deucravacitinib group was nasopharyngitis.
Conclusion
Oral administration of Deucravacitinib is effective for moderate to severe plaque psoriasis. Attention should be paid to the occurrence of AEs, and more RCTs are required to evaluate the relationship between the dose and safety and efficacy.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Dermatology, the Forth Hospital of Hebei Medical University, Shijiazhuang, China.
Cite
APA
Hu, C., Han, X., Cui, Y., Zhang, Y., & Cheng, Y. (2024). Safety and efficacy of Deucravacitinib for moderate to severe plaque psoriasis: A meta‐analysis. Skin Research and Technology. https://doi.org/10.1111/srt.13855
Vancouver
Hu C, Han X, Cui Y, Zhang Y, Cheng Y. Safety and efficacy of Deucravacitinib for moderate to severe plaque psoriasis: A meta‐analysis. Skin Research and Technology. 2024. doi:10.1111/srt.13855
BibTeX
@article{Hu2024,
author = {Hu, Caixia and Han, Xiaomei and Cui, Yu and Zhang, Yan and Cheng, Yi},
title = {Safety and efficacy of Deucravacitinib for moderate to severe plaque psoriasis: A meta‐analysis},
journal = {Skin Research and Technology},
year = {2024},
doi = {10.1111/srt.13855}
}
EUVIMED